BPMCBlueprint Medicines Corp

Nasdaq blueprintmedicines.com


$ 93.06 $ 2.27 (2.5 %)    

Friday, 26-Apr-2024 15:59:54 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 93
$ 92.94
$ 93.00 x 100
$ 0.00 x 0
$ 91.19 - $ 94.97
$ 43.89 - $ 101.00
725,963
na
5.63B
$ 1.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-15-2024 12-31-2023 10-K
2 10-26-2023 09-30-2023 10-Q
3 08-02-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 02-16-2023 12-31-2022 10-K
6 11-01-2022 09-30-2022 10-Q
7 08-02-2022 06-30-2022 10-Q
8 05-03-2022 03-31-2022 10-Q
9 02-17-2022 12-31-2021 10-K
10 10-28-2021 09-30-2021 10-Q
11 07-29-2021 06-30-2021 10-Q
12 04-29-2021 03-31-2021 10-Q
13 02-17-2021 12-31-2020 10-K
14 10-29-2020 09-30-2020 10-Q
15 07-31-2020 06-30-2020 10-Q
16 05-06-2020 03-31-2020 10-Q
17 02-13-2020 12-31-2019 10-K
18 11-05-2019 09-30-2019 10-Q
19 08-01-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 02-26-2019 12-31-2018 10-K
22 10-30-2018 09-30-2018 10-Q
23 08-01-2018 06-30-2018 10-Q
24 05-02-2018 03-31-2018 10-Q
25 02-21-2018 12-31-2017 10-K
26 10-31-2017 09-30-2017 10-Q
27 08-02-2017 06-30-2017 10-Q
28 05-03-2017 03-31-2017 10-Q
29 03-09-2017 12-31-2016 10-K
30 11-10-2016 09-30-2016 10-Q
31 08-09-2016 06-30-2016 10-Q
32 05-10-2016 03-31-2016 10-Q
33 03-11-2016 12-31-2015 10-K
34 11-09-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 06-11-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stifel-maintains-buy-on-blueprint-medicines-raises-price-target-to-130

Stifel analyst Bradley Canino maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $120 t...

 wedbush-reiterates-outperform-on-blueprint-medicines-maintains-110-price-target

Wedbush analyst David Nierengarten reiterates Blueprint Medicines (NASDAQ:BPMC) with a Outperform and maintains $110 price t...

 hc-wainwright--co-reiterates-buy-on-blueprint-medicines-maintains-125-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $125 price...

 needham-reiterates-buy-on-blueprint-medicines-maintains-97-price-target

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $97 price target.

 jmp-securities-reiterates-market-outperform-on-blueprint-medicines-maintains-114-price-target

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and maintains $11...

 needham-reiterates-buy-on-blueprint-medicines-maintains-97-price-target

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $97 price target.

 blueprint-medicines-highlights-ayvakit-long-term-efficacy-and-safety-data-and-advances-in-mast-cell-disease-research-at-2024-aaaai-annual-meeting

-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term...

Core News & Articles

GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell l...

 jmp-securities-reiterates-market-outperform-on-blueprint-medicines-maintains-114-price-target

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and maintains $11...

 reliance-steel--aluminum-posts-upbeat-earnings-joins-jfrog-applovin-shake-shack-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.

 blueprint-medicines-q4-eps-182-beats-204-estimate-sales-7196m-beat-6664m-estimate

Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $...

 earnings-scheduled-for-february-15-2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

 jmp-securities-reiterates-market-outperform-on-blueprint-medicines-maintains-114-price-target

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and maintains $11...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION